1. Home
  2. REPL

as 06-20-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Founded: 2015 Country:
United States
United States
Employees: N/A City: WOBURN
Market Cap: 320.6M IPO Year: 2018
Target Price: $34.00 AVG Volume (30 days): 1.7M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.24 EPS Growth: N/A
52 Week Low/High: $4.92 - $24.28 Next Earning Date: 08-01-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 175.17%

REPL Daily Stock ML Predictions

Stock Insider Trading Activity of Replimune Group Inc. (REPL)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Love Colin REPL Chief Operating Officer May 16 '24 Sell $6.47 17,615 $113,969.05 777,345 SEC Form 4
Astley-Sparke Philip REPL Executive Chairman May 16 '24 Sell $6.47 37,928 $245,394.16 1,487,350 SEC Form 4
Coffin Robert REPL Director May 16 '24 Sell $6.47 11,464 $74,172.08 1,821,872 SEC Form 4
Schwendenman Andrew REPL Chief Accounting Officer May 16 '24 Sell $6.47 2,298 $14,868.06 38,238 SEC Form 4
Patel Sushil REPL Chief Executive Officer May 16 '24 Sell $6.47 20,194 $130,655.18 212,014 SEC Form 4
Xynos Konstantinos REPL Chief Medical Officer May 16 '24 Sell $6.47 6,367 $41,194.49 133,012 SEC Form 4
Sarchi Christopher REPL Chief Commercial Officer May 16 '24 Sell $6.47 2,218 $14,350.46 92,252 SEC Form 4
Xynos Konstantinos REPL Chief Medical Officer Nov 16 '23 Sell $10.92 7,313 $79,857.96 112,714 SEC Form 4

Share on Social Networks: